| Regulation of IRF-3-dependent innate immunity by the papain-like protease domain of the severe acute respiratory syndrome coronavirus SG Devaraj, N Wang, Z Chen, Z Chen, M Tseng, N Barretto, R Lin, ... Journal of Biological Chemistry 282 (44), 32208-32221, 2007 | 436 | 2007 |
| Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells W Fiskus, S Sharma, B Shah, BP Portier, SGT Devaraj, K Liu, SP Iyer, ... Leukemia 28 (11), 2155-2164, 2014 | 292 | 2014 |
| Toll-like receptor 3 mediates establishment of an antiviral state against hepatitis C virus in hepatoma cells N Wang, Y Liang, S Devaraj, J Wang, SM Lemon, K Li Journal of virology 83 (19), 9824-9834, 2009 | 255 | 2009 |
| Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells W Fiskus, S Sharma, J Qi, JA Valenta, LJ Schaub, B Shah, K Peth, ... Molecular cancer therapeutics 13 (5), 1142-1154, 2014 | 203 | 2014 |
| Histone deacetylase inhibitor treatment induces ‘BRCAness’ and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells K Ha, W Fiskus, DS Choi, S Bhaskara, L Cerchietti, SGT Devaraj, B Shah, ... Oncotarget 5 (14), 5637, 2014 | 157 | 2014 |
| Ubiquitination and proteasomal degradation of interferon regulatory factor-3 induced by Npro from a cytopathic bovine viral diarrhea virus Z Chen, R Rijnbrand, RK Jangra, SG Devaraj, L Qu, Y Ma, SM Lemon, ... Virology 366 (2), 277-292, 2007 | 152 | 2007 |
| BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD W Fiskus, S Sharma, J Qi, B Shah, SGT Devaraj, C Leveque, BP Portier, ... Molecular cancer therapeutics 13 (10), 2315-2327, 2014 | 150 | 2014 |
| Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib B Sun, B Shah, W Fiskus, J Qi, K Rajapakshe, C Coarfa, L Li, ... Blood, The Journal of the American Society of Hematology 126 (13), 1565-1574, 2015 | 118 | 2015 |
| Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells W Fiskus, S Sharma, S Saha, B Shah, SGT Devaraj, B Sun, S Horrigan, ... Leukemia 29 (6), 1267-1278, 2015 | 115 | 2015 |
| A molecular switch in the capsid protein controls the particle polymorphism in an icosahedral virus GL Lokesh, TDS Gowri, PS Satheshkumar, MRN Murthy, HS Savithri Virology 292 (2), 211-223, 2002 | 71 | 2002 |
| Complete genomic sequence of Pepper vein banding virus (PVBV): a distinct member of the genus Potyvirus R Anindya, J Joseph, TDS Gowri, HS Savithri Archives of virology 149, 625-632, 2004 | 48 | 2004 |
| HEXIM1 induction is mechanistically involved in mediating anti-AML activity of BET protein bromodomain antagonist SGT Devaraj, W Fiskus, B Shah, J Qi, B Sun, SP Iyer, S Sharma, ... Leukemia 30 (2), 504-508, 2016 | 40 | 2016 |
| Erratum: Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells W Fiskus, S Sharma, B Shah, BP Portier, SGT Devaraj, K Liu, SP Iyer, ... Leukemia 31 (7), 1658-1658, 2017 | 19 | 2017 |
| DNA aptamer against anti-programmed cell death-1 (anti-PD1-apt) induces robust anti-leukemic activity in vitro and in vivo humanized NSG mice with myeloid leukemia xenografts SGT Devaraj, LGL Rao, Y Zu, J Chang, SP Iyer Blood 130, 1373, 2017 | 5 | 2017 |
| Peters. CJ Tseng, CK, Baker, SC, Li, K. Regulation of IRF-3-dependent innate immunity by the papain-like protease domain of the severe acute respiratory syndrome coronavirus SG Devaraj, N Wang, Z Chen, Z Chen J Biol Chem 282, 32208-32221, 2007 | 4 | 2007 |
| Mechanistic role of HEXIM1 induction in BRD4-antagonist mediated growth inhibition, differentiation and in vivo lethal activity against human aml blast progenitor cells SGT Devaraj, W Fiskus, B Shah, S Sharma, J Qi, B Sun, S Saha, SP Iyer, ... Blood 124 (21), 3534, 2014 | 2 | 2014 |
| Superior Pre-Clinical Activity of BET (Bromodomain and Extra terminal) Protein Antagonist Combined with Ibrutinib, Panobinostat or Carfilzomib Against Human Mantle Cell … B Sun, W Fiskus, B Shah, J Qi, SGT Devaraj, SP Iyer, S Sharma, ... Blood 124 (21), 918, 2014 | 1 | 2014 |
| HEXIM1 induction exerts a mechanistic role and is a biomarker of lethal activity of BRD4 antagonist against human AML cells SGT Devaraj, W Fiskus, S Sharma, J Qi, B Shah, LJ Schaub, M Rodriguez, ... Cancer Research 74 (19_Supplement), 3686-3686, 2014 | 1 | 2014 |
| BRD4 antagonist-based therapy exerts lethal activity against FLT3 mutation expressing AML cells resistant to FLT3 tyrosine kinase inhibitors M Rodriguez, W Fiskus, S Sharma, J Qi, LJ Schaub, B Shah, SGT Devaraj, ... Cancer Research 74 (19_Supplement), 1721-1721, 2014 | 1 | 2014 |
| Combined Therapy With BRD4 Antagonist and JAK Inhibitor Is Synergistically Lethal Against Human Myeloproliferative Neoplasm (MPN) Cells JA Valenta, W Fiskus, T Manshouri, S Sharma, J Qi, LJ Schaub, B Shah, ... Blood 122 (21), 2842, 2013 | 1 | 2013 |
